|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent No. 11,033,543: Ophthalmic Formulations
U.S. Patent No. 11,033,543, issued on June 15, 2021, to Novartis AG, claims novel ophthalmic formulations designed for the treatment of eye diseases, specifically targeting glaucoma and ocular hypertension. The patent centers on improved compositions that enhance the solubility and bioavailability of active pharmaceutical ingredients (APIs), primarily prostaglandin analogs.
What is the Core Invention Claimed by U.S. Patent No. 11,033,543?
The primary invention protected by U.S. Patent No. 11,033,543 is an ophthalmic formulation comprising a prostaglandin analog and a specific combination of excipients. The key innovation lies in the use of certain solubilizing agents and stabilizers that overcome the poor aqueous solubility of prostaglandin analogs, leading to improved efficacy and potentially reduced dosing frequency or concentration. The patent also covers methods of preparing these formulations and methods of treating ocular conditions using them.
What is the Scope of the Patent's Claims?
U.S. Patent No. 11,033,543 encompasses a series of claims detailing the composition and use of its ophthalmic formulations.
- Claim 1 defines a pharmaceutical composition for treating a disease or condition of the eye. This claim specifies the inclusion of a prostaglandin analog, a non-ionic surfactant, a non-ionic co-surfactant, and an acidic buffer. The acidic buffer is characterized by a pH of between 3.5 and 5.5. The patent specifies that the prostaglandin analog is present in an amount of 0.0001% to 0.01% by weight of the composition.
- Claim 2 builds upon Claim 1, further specifying that the prostaglandin analog is selected from a list including travoprost, latanoprost, bimatoprost, tafluprost, and unoprostone.
- Claim 3 narrows the scope of Claim 1 by defining the non-ionic surfactant as having an HLB (Hydrophilic-Lipophilic Balance) value of 10 to 18.
- Claim 4 refines Claim 1 by specifying the non-ionic co-surfactant as having an HLB value of 14 to 18.
- Claim 5 further details the composition from Claim 1, stating that the non-ionic surfactant is selected from a group consisting of polysorbate 20, polysorbate 80, and Cremophor EL.
- Claim 6 specifies the non-ionic co-surfactant from Claim 1 to be a polyoxyethylene sorbitan fatty acid ester.
- Claim 7 delineates the acidic buffer in Claim 1, stating it is selected from acetate buffer, citrate buffer, and phosphate buffer.
- Claim 8 provides an example of the composition by defining a specific formulation containing travoprost, polysorbate 80, Cremophor RH 40, acetate buffer, and water.
- Claim 9 extends the patent to methods of preparing the pharmaceutical composition described in Claim 1.
- Claim 10 outlines a method for treating a disease or condition of the eye, involving administering the pharmaceutical composition of Claim 1 to a subject in need thereof.
What are the Key Technical Aspects of the Patented Formulations?
The patent emphasizes specific formulation characteristics aimed at enhancing drug delivery and stability.
Excipient Functions and Specifications
The disclosed formulations rely on a precise combination of excipients to achieve their therapeutic goals.
- Prostaglandin Analog: These are the active pharmaceutical ingredients (APIs) designed to reduce intraocular pressure (IOP). The patent includes several common prostaglandin analogs known for their efficacy but also their formulation challenges due to poor water solubility.
- Examples: Travoprost, Latanoprost, Bimatoprost, Tafluprost, Unoprostone.
- Concentration: Typically 0.0001% to 0.01% by weight.
- Non-ionic Surfactant: This component is crucial for solubilizing the lipophilic prostaglandin analog in an aqueous vehicle. The selection is based on its HLB value.
- HLB Value: 10 to 18.
- Examples: Polysorbate 20, Polysorbate 80, Cremophor EL.
- Non-ionic Co-surfactant: Works in synergy with the primary surfactant to further improve solubility and potentially enhance formulation stability and drug penetration.
- HLB Value: 14 to 18.
- Examples: Polyoxyethylene sorbitan fatty acid esters (e.g., Cremophor RH 40).
- Acidic Buffer: The pH of the formulation is critical for API stability and ocular comfort. An acidic pH range is specified to maintain the integrity of the prostaglandin analog.
- pH Range: 3.5 to 5.5.
- Examples: Acetate buffer, Citrate buffer, Phosphate buffer.
Advantages of the Patented Formulation
The patent highlights several benefits derived from its specific formulation approach:
- Improved Solubility: The combination of non-ionic surfactants with specific HLB values effectively solubilizes poorly soluble prostaglandin analogs, enabling higher drug concentrations or more consistent delivery.
- Enhanced Bioavailability: By improving solubility, the formulation facilitates better absorption of the API into ocular tissues, potentially leading to increased therapeutic effect.
- Increased Stability: The acidic pH range and surfactant system contribute to the chemical stability of the prostaglandin analog, extending its shelf life and maintaining its potency.
- Reduced Irritation: Optimized formulation can potentially minimize ocular side effects such as redness and irritation, which are sometimes associated with prostaglandin analog eye drops.
What is the Patent Landscape for Ophthalmic Prostaglandin Analog Formulations?
The patent landscape for ophthalmic prostaglandin analogs is crowded, with numerous patents covering active ingredients, formulations, and methods of use. U.S. Patent No. 11,033,543 occupies a specific niche within this landscape by focusing on a particular combination of excipients and pH to overcome known formulation challenges.
Key Competitors and Their IP Strategies
Major pharmaceutical companies involved in the development of glaucoma and ocular hypertension treatments hold significant patent portfolios.
- Allergan (now AbbVie): Historically a leader with products like Lumigan (bimatoprost) and Travatan (travoprost). Allergan possesses a broad patent portfolio covering various formulations and delivery systems for these drugs.
- Pfizer: Holds patents related to latanoprost formulations, including its blockbuster product Xalatan.
- Santen Pharmaceutical: Has developed and patented ophthalmic formulations, including tafluprost-based products.
- Bausch Health: Offers prostaglandin analog products and holds associated intellectual property.
Novartis AG, the assignee of U.S. Patent No. 11,033,543, is also a significant player with products like Xiidra (lifitegrast) for dry eye, demonstrating a broad interest in ophthalmic therapeutics. The specific formulation claimed in 11,033,543 likely aims to create a differentiated product or offer a superior alternative to existing prostaglandin analog eye drops.
Overlapping Technologies and Potential Infringement Concerns
Companies developing new ophthalmic prostaglandin analog formulations must navigate existing patents carefully.
- Composition of Matter Patents: These are the strongest patents, covering the API itself. Most primary prostaglandin analogs have expired or are nearing expiration.
- Formulation Patents: These patents, like U.S. Patent No. 11,033,543, protect specific combinations of APIs with excipients, manufacturing processes, and dosage forms. These are critical for generic manufacturers and innovators seeking to differentiate their products.
- Method of Use Patents: These patents cover specific indications or methods of administering the drug.
Companies seeking to develop or market generic versions of prostaglandin analog eye drops, or novel formulations of these APIs, must conduct thorough freedom-to-operate (FTO) analyses. This includes evaluating the claims of U.S. Patent No. 11,033,543 and other relevant patents to avoid infringement. The specific excipient combinations and pH ranges claimed in 11,033,543 represent potential hurdles for competitors.
What are the Commercial Implications of U.S. Patent No. 11,033,543?
This patent grants Novartis AG exclusive rights to its claimed ophthalmic formulations, impacting market competition and the development of new treatments for glaucoma and ocular hypertension.
Market Exclusivity and Differentiation
The patent provides a period of market exclusivity for formulations that fall within its claimed scope. This allows Novartis to potentially:
- Develop and commercialize a new branded product based on this patented technology.
- Differentiate its offerings from existing generic prostaglandin analog eye drops by highlighting improved solubility, bioavailability, or reduced side effects, as suggested by the patent’s technical disclosures.
- Command premium pricing for a product protected by this intellectual property.
Impact on Generic Competition
For generic manufacturers, U.S. Patent No. 11,033,543 presents a barrier. They must:
- Design Around: Develop formulations that do not infringe the specific claims of this patent. This would involve using different excipients, different concentrations, or operating outside the specified pH range, while still achieving therapeutic efficacy.
- Challenge the Patent: Attempt to invalidate the patent through post-grant review proceedings or litigation, though this is a complex and costly process.
- Wait for Expiration: Launch generic versions only after the patent expires, which is June 15, 2041 (20 years from the filing date of the earliest claimed priority application plus potential patent term extensions).
Investment and R&D Strategy
From an investment and R&D perspective, U.S. Patent No. 11,033,543 suggests:
- Niche Opportunities: There remains opportunity for innovation in ophthalmic drug delivery for well-established APIs if novel formulation strategies can be patented.
- Focus on Bioavailability and Stability: Investors may look favorably upon companies with strong IP protection for formulations that demonstrably improve drug delivery and patient outcomes.
- Due Diligence: Thorough IP due diligence is essential when considering investments in companies developing treatments in this therapeutic area, especially concerning existing formulation patents.
Key Takeaways
U.S. Patent No. 11,033,543, assigned to Novartis AG, protects specific ophthalmic formulations for treating glaucoma and ocular hypertension. The core of the invention is a composition comprising a prostaglandin analog, a non-ionic surfactant with an HLB of 10-18, a non-ionic co-surfactant with an HLB of 14-18, and an acidic buffer (pH 3.5-5.5). These formulations aim to enhance the solubility, bioavailability, and stability of prostaglandin analogs. The patent landscape for prostaglandin analog eye drops is competitive, with existing intellectual property held by major pharmaceutical companies. This patent represents a potential barrier for generic manufacturers and highlights opportunities for developing differentiated, proprietary formulations.
Frequently Asked Questions
-
What specific disease indications does U.S. Patent No. 11,033,543 cover?
The patent covers methods for treating a disease or condition of the eye, specifically referencing glaucoma and ocular hypertension through the use of prostaglandin analogs.
-
Can generic versions of prostaglandin analog eye drops be formulated without infringing this patent?
Generic manufacturers can attempt to design around the patent by using alternative excipients, different HLB values for surfactants, or formulations outside the specified pH range, provided these alternatives do not fall within the patent's claimed scope.
-
What is the expiration date of U.S. Patent No. 11,033,543?
The patent is expected to expire on June 15, 2041, barring any extensions.
-
Does the patent claim the active pharmaceutical ingredient (API) itself?
No, U.S. Patent No. 11,033,543 claims specific ophthalmic formulations and methods of use, not the prostaglandin analog API itself, which are typically covered by separate, earlier patents.
-
What are the typical concentrations of prostaglandin analogs mentioned in the patent?
The patent specifies that the prostaglandin analog is present in an amount of 0.0001% to 0.01% by weight of the composition.
Citations
[1] U.S. Patent No. 11,033,543 (2021, June 15). Ophthalmic Formulations. Novartis AG.
More… ↓
⤷ Start Trial
|
